V205C, measles, mumps, and rubella virus vaccine live + Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Measles
Conditions
Measles
Trial Timeline
Oct 1, 2004 → May 1, 2005
NCT ID
NCT00109278About V205C, measles, mumps, and rubella virus vaccine live + Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
V205C, measles, mumps, and rubella virus vaccine live + Comparator: Measles, Mumps, and Rubella Virus Vaccine Live is a phase 2 stage product being developed by Merck for Measles. The current trial status is completed. This product is registered under clinical trial identifier NCT00109278. Target conditions include Measles.
What happened to similar drugs?
4 of 18 similar drugs in Measles were approved
Approved (4) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00109278 | Phase 2 | Completed |
Competing Products
20 competing products in Measles